Minerva Neurosciences, Inc.NERVNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+40.1%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+40.1%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
5.4x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 46.43% |
| Q3 2025 | -7.63% |
| Q2 2025 | -18.28% |
| Q1 2025 | 0.05% |
| Q4 2024 | 2.44% |
| Q3 2024 | 2.55% |
| Q2 2024 | -3.88% |
| Q1 2024 | 2.59% |
| Q4 2023 | -6.99% |
| Q3 2023 | 0.12% |
| Q2 2023 | -2.32% |
| Q1 2023 | 43.36% |
| Q4 2022 | -33.80% |
| Q3 2022 | 0.23% |
| Q2 2022 | -6.48% |
| Q1 2022 | 15.14% |
| Q4 2021 | -12.44% |
| Q3 2021 | -12.71% |
| Q2 2021 | -18.98% |
| Q1 2021 | 13.36% |
| Q4 2020 | 8.59% |
| Q3 2020 | -41.51% |
| Q2 2020 | 40.87% |
| Q1 2020 | 9.01% |
| Q4 2019 | -16.58% |
| Q3 2019 | 0.50% |
| Q2 2019 | -2.59% |
| Q1 2019 | 1.86% |
| Q4 2018 | 13.93% |
| Q3 2018 | 4.73% |
| Q2 2018 | -9.85% |
| Q1 2018 | 43.55% |
| Q4 2017 | 22.07% |
| Q3 2017 | -5.77% |
| Q2 2017 | -9.40% |
| Q1 2017 | 4.82% |
| Q4 2016 | 15.08% |
| Q3 2016 | 5.78% |
| Q2 2016 | -5.54% |
| Q1 2016 | 23.10% |